Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled colistimethate sodium versus placebo for non-cystic fibrosis bronchiectasis with chronic Pseudomonas aeruginosa infection
MOH_2020-07-02_009055Phase 3Completed
- Sponsor
- Zambon
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of colistimethate sodium in bronchiectasis (2 arms), sponsored by Zambon. Primary endpoint: Frequency of pulmonary exacerbations. Started May 2020; status: completed.
02
Drugs
colistimethate sodium
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on MOH_2020-07-02_009055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-02_009055.